2024-05-28 00:08:10 ET
Summary
- FibroGen focuses on developing Pamrevlumab for pancreatic cancer therapy after disappointing trial results for other indications.
- If successful, Pamrevlumab’s phase 3 trials in pancreatic cancer could be a major value driver.
- Roxadustat has already been approved for anemia in chronic kidney disease and is in phase 3 for chemotherapy-induced anemia.
- FibroGen's financials show signs of deterioration and structural unprofitability, raising concerns about its prospects.
- Despite financial concerns and R&D issues, the stock trades at a significant discount relative to peers, justifying a "hold" rating.
...
Read the full article on Seeking Alpha
For further details see:
Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains